MiniMed Flex (formerly NMX8-AID)
MiniMed
What it is
MiniMed's FDA-cleared, screenless, smartphone-controlled successor to the 780G pump line. Flex uses SmartGuard advanced hybrid closed-loop automation, Simplera Sync or Instinct CGM, a 300-unit reservoir, 7-day rechargeable battery and app bolusing. GATEWAY — an interventional safety study, not a passive registry — still tests it under the NMX8-AID name and includes flexible/no-meal-bolus arms, but public Flex performance data are not yet as mature as 780G real-world data.
Editorial review: .
Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Time in range: Uses MiniMed SmartGuard automation, whose predecessor 780G has strong real-world evidence, but Flex-specific GATEWAY outcomes are not posted yet; scored below mature 780G until direct data report.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 70 × 20 + 72 × 20 + 70 × 10 + 62 × 20 + 68 × 5 + 66 × 5 + 58 × 5 + 62 × 5 + 55 × 10 = 6600; divide by total weight 100. Unrounded weighted result: 66.
Uses MiniMed SmartGuard automation, whose predecessor 780G has strong real-world evidence, but Flex-specific GATEWAY outcomes are not posted yet; scored below mature 780G until direct data report.[1]
SmartGuard includes predictive low suspend and automated basal/correction behavior, and the GATEWAY safety study directly measures time below 70 mg/dL (3.9 mmol/L), but Flex-specific safety outcomes are still pending — primary completion is not due until January 2027.[3]
Product release is an advanced hybrid loop with app bolusing; GATEWAY randomises participants to bolus, not bolus, or bolus at will for meals, making this a real step toward lower-burden meal automation. Scored on the shipped hybrid loop, not on the unproven no-bolus arm.[3]
Smaller, screenless, smartphone-controlled pump with app meal/correction boluses and a 7-day battery is freer than a classic pump body, but it remains tubed.[1]
Expected to inherit SmartGuard glucose performance, but no Flex-specific mean glucose, GMI, or HbA1c results have been posted.[1]
SmartGuard should reduce excursions through automated correction and basal changes, but GATEWAY variability results are still unavailable.[3]
The safety study collects exercise logs and SmartGuard includes low protection, but no Flex-specific exercise-mode results are public.[3]
The system supports app control, SmartGuard settings, and the meal modes under study, but it remains a closed MiniMed ecosystem rather than a deeply tunable algorithm.[1]
FDA-cleared in the US for T1D ages 7+ and insulin-requiring T2D adults, commercially launched in June 2026 and available to Medicare and Medicare Advantage beneficiaries since 22 July. Beyond the announced CE mark and targeted November 2026 European launch, ex-US rollout is still unclear.[4]
AID default: 50% glucose outcomes and low-glucose protection, 40% daily experience, 10% access and cost. Freedom includes tubing, wearability, water-use limits and controller requirements. These are editorial priorities; studies and device generations differ. Check each scorecard for its evidence and limits.
The full picture
MiniMed Flex is the public product name for the next-generation system that the GATEWAY study still calls NMX8-AID. It is now FDA-cleared in the United States: a small screenless pump controlled through the MiniMed app, paired with SmartGuard automation, Simplera Sync CGM, standard MiniMed infusion sets, a 300-unit reservoir and a rechargeable battery lasting at least seven days. The US commercial rollout, with Simplera Sync as the paired sensor, has been running through the summer of 2026, and access expanded to Medicare and Medicare Advantage beneficiaries on 22 July.4
The reason it stays in the "frontier" set is the GATEWAY protocol. GATEWAY is an interventional safety study — not a passive registry — with actual enrollment of 389 people and randomising them to bolus, not bolus, or bolus at will for meals. A licensed system with a formally studied no-meal-bolus arm is a direct move toward lower-burden meal automation.
The caveat is evidence maturity, and it has not changed. The pump is cleared, but public Flex-specific time-in-range, hypoglycemia and no-meal-bolus outcomes are not posted yet; GATEWAY's primary completion is not due until January 2027. Everything we currently score is inherited from SmartGuard's track record on the 780G, not measured on Flex. Until direct results arrive, Flex should be treated as an approved hardware and control upgrade with a promising automation direction, not as proven fully closed loop.
What is reported next — and how firmly
Flex is also the platform MiniMed has said will carry Vivera, a next generation algorithm whose headline promise is making the meal bolus optional rather than required. On 17 August 2026 MiniMed announced Flex is commercially shipping in the US with the Abbott-built Instinct sensor, so Instinct is no longer a summer promise.5 European CE marking was announced on 1 September 2026; launch is targeted for November 2026.7
September regulatory update. Flex has received CE marking, with European launch targeted November 2026. US commercial availability does not imply that European sales have begun.7
What's next for this
- →European launch following CE mark; company target, not current European availability · November 2026
- →Vivera fully closed-loop algorithm, subject to regulatory review · US launch targeted second half of 2027
Sources
- [1]MiniMed Flex system product FAQ · Manufacturer
- [2]
- [3]GATEWAY Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes · Trial registry · 2026-06-08 — NCT07228117. Interventional safety study (not a passive registry), actual n=389, active, not recruiting, started 2 Feb 2026, primary completion January 2027. Randomises participants to bolus, not bolus, or bolus at will for meals.
- [4]MiniMed Flex now available to Medicare and Medicare Advantage beneficiaries · Manufacturer · 2026-07-22 — Confirms Medicare access. Instinct compatibility was still future as of this 22 July 2026 page; shipping began 17 August 2026 (see flex-instinct-ship).
MiniMed. MiniMed Flex Now Available to Medicare and Medicare Advantage Beneficiaries (22 July 2026).
- [5]MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor · Manufacturer · 2026-08-17 — US Flex+Instinct commercial shipping. Not Flex-specific TIR data.
MiniMed. MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor (17 August 2026).
- [6]Closed-loop updates from ADA 2026: MiniMed Flex, Instinct and Vivera · Open-source community · 2026-06-25 — Community conference recap, not a company announcement. Sole source for the reported Instinct-integration and European-launch timings, so those are attributed rather than stated as fact.
- [7]MiniMed September 2026 pipeline and launch update · Manufacturer · 2026-09-01
MiniMed. September 2026 pipeline and commercial update.